This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

Baricitinib in Alopecia Areata

List of authors.
  • Andrew Messenger, M.D.,
  • and Matthew Harries, Ph.D.

For many people, alopecia areata is a transient problem, in which small patches of hair loss recover spontaneously within a few months. But for others, the reality is rather different. An Italian study showed that one third of patients with scalp hair loss of 25 to 50% still had active patchy disease at long-term follow-up, with a further third having progression to alopecia totalis or alopecia universalis, terms that vividly capture the extreme extent of disease and from which recovery is rare.1 For many patients with severe disease, medical treatments do not work, and they face difficulty in coping with . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.

Author Affiliations

From the Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield (A.M.), the Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford (M.H.), and the Centre for Dermatology Research, University of Manchester, Manchester Academic Health Science Centre and National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.H.) — all in the United Kingdom.

Print Subscriber? Activate your online access.